€15.10
Your prediction
Avadel Pharmaceuticals plc ADR Stock
Pros and Cons of Avadel Pharmaceuticals plc ADR in the next few years
Pros
Cons
Performance of Avadel Pharmaceuticals plc ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Avadel Pharmaceuticals plc ADR | 0.670% | - | - | - | - | - | - |
| Valneva SE | -1.840% | -0.964% | 6.598% | -22.756% | -22.416% | -68.076% | 5.413% |
| Nanobiotix | 3.580% | 1.823% | -6.272% | 54.665% | -17.368% | -59.380% | -54.029% |
| Transgene S.A. | -3.080% | -2.014% | 21.174% | -29.721% | 1.642% | -45.301% | -52.294% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon examining the financials of Avadel Pharmaceuticals, a company operating in the Biotechnology & Medical Research industry under the US stock symbol FLML, it is apparent that the company has faced financial challenges over the past few years. The main striking points are the absence of reported revenue, significant net losses, and a negative total stockholder equity. However, the company has a strong cash position which may offer some cushioning against financial difficulties. This article will carefully analyze the financial strengths and weaknesses of Avadel Pharmaceuticals, offering insights into the company's current financial status and future prospects.
Cash and Short-term Investments: Avadel Pharmaceuticals maintains a substantial cash position, with $73,981,000 at the end of 2022, up from $50,708,000 in 2021. Additionally, the company holds $22,518,000 in short-term investments, reflecting their ability to secure liquid assets that could be utilized for research and development, debt servicing, or potential acquisitions.
Net Working Capital: Despite facing losses in recent years, Avadel Pharmaceuticals boasts a positive net working capital of $45,050,000 as of 2022, up from a significant $171,490,000 in 2021. This indicates that the company has enough liquid assets to cover its short-term liabilities, which is crucial in maintaining financial stability.